Cure My Disease

Don't miss your cure!

 Log in / Sign up

New daily pill could help millions lose weight and control diabetes

NCT ID NCT06972472

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing a once-daily pill called orforglipron in 600 adults who are overweight or have obesity and also have type 2 diabetes. The study compares the drug to a placebo to see if it helps lower blood sugar and body weight over about 18 months. Participants must have a BMI of 25 or higher and have tried to lose weight before without lasting success.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
orforglipron (a daily pill)
What this could lead to
If it works, this could lead to a new once-daily pill that helps people with obesity and type 2 diabetes lose weight and better control their blood sugar.
What could go wrong
This is still a Phase 3 trial, so results are not yet confirmed. The drug may not work better than placebo, and side effects are possible. It is not a cure—ongoing management of diabetes and weight is still needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening * Have type 2 diabetes * Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening * Have a history of at least one unsuccessful dietary effort to lose body weight Exclusion Criteria: * Have type 1 diabetes * Have an unstable body weight within 90 days prior to screening * Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening * Have acute or chronic hepatitis or pancreatitis * Are taking other medications or alternative remedies to manage weight loss

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight Type 2 diabetes

Contacts and locations

Locations

  • Accel Research Sites - DeLand Clinical Research Unit

    DeLand, Florida, 32720, United States

  • Accel Research Sites - NeuroStudies Clinical Research Unit

    Decatur, Georgia, 30030, United States

  • Activian Clinical Research

    Kingwood, Texas, 77339, United States

  • AmBeNet GmbH

    Leipzig, 04107, Germany

  • Biopharma Informatic, LLC

    Houston, Texas, 77043, United States

  • Boeson Research MSO

    Missoula, Montana, 59804, United States

  • CARE - Centro de Alergia y Enfermedades Respiratorias

    Buenos Aires, 1414, Argentina

  • CIPREC

    Buenos Aires, C1119ACN, Argentina

  • Care Access - Decatur

    Decatur, Georgia, 30030, United States

  • Care Access - Fayetteville

    Fayetteville, North Carolina, 28314, United States

  • Care Access - New Iberia

    New Iberia, Louisiana, 70560, United States

  • Care Access - Tampa

    Tampa, Florida, 33625, United States

  • Care Access - Thousand Oaks

    Thousand Oaks, California, 91360, United States

  • Centro Médico Viamonte

    Buenos Aires, C1120AAC, Argentina

  • Centro de Diagnóstico y Rehabilitación (CEDIR)

    Santa Fe, 3000, Argentina

  • Clinical Research Institute of Arizona (CRI) - Sun City West

    Sun City West, Arizona, 85375, United States

  • Clinical Research of Philadelphia

    Philadelphia, Pennsylvania, 19114, United States

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231, United States

  • Diabetes Zentrum Wilhelmsburg

    Hamburg, 21109, Germany

  • Donmed s.r.o.

    Ostrava, 710 00, Czechia

  • Encore Medical Research

    Hollywood, Florida, 33024, United States

  • Endocrine and Metabolic Consultants

    Rockville, Maryland, 20852, United States

  • Frontier Clinical Research, LLC

    Smithfield, Pennsylvania, 15478, United States

  • Fukuwa Clinic

    Chūōku, 104-0031, Japan

  • Gemeinschaftspraxis Dr. Taeschner/Dr. Bonigut

    Leipzig, 04249, Germany

  • Great Lakes Research Group, Inc.

    Bay City, Michigan, 48706, United States

  • Hasegawa Medicine Clinic

    Chitose, 066-0032, Japan

  • Indago Research & Health Center, Inc

    Hialeah, Florida, 33012, United States

  • InnoDiab Forschung Gmbh

    Essen, 45136, Germany

  • Innovation Medical Research Center - Fort Lauderdale

    Fort Lauderdale, Florida, 33316, United States

  • Instituto Centenario

    CABA, 1204, Argentina

  • Instituto Médico Catamarca IMEC

    Rosario, 2000, Argentina

  • Isis Clinical Research Center

    Guaynabo, 00968, Puerto Rico

  • Javara - Nevada Health Centers - Carson City

    Carson City, Nevada, 89706, United States

  • Javara - Privia Medical Group - Silver Spring

    Silver Spring, Maryland, 20901, United States

  • Javara - Privia Medical Group Georgia - Savannah

    Savannah, Georgia, 31406, United States

  • Javara - Tryon Medical Partners

    Charlotte, North Carolina, 28210, United States

  • Jinan Central Hospital

    Jinan, 250013, China

  • MUDr. Alena Vachova

    České Budějovice, 37011, Czechia

  • Medical Corporation Heishinkai OCROM Clinic

    Suita-shi, 565-0853, Japan

  • Medical Corporation Heishinkai ToCROM Clinic

    Shinjuku-ku, 160-0008, Japan

  • Medical Corporation Yuga Tsuruma Kaneshiro Diabetes Clinic

    Yamato-shi, 242-0004, Japan

  • Medical Plus

    Uherské Hradiště, 686 01, Czechia

  • Medicover Neuroendokrinologie

    Munich, 81667, Germany

  • Medizentrum Essen Borbeck

    Essen, 45355, Germany

  • Milan Kvapil s.r.o., Diabetologicka ambulance

    Prague, 14900, Czechia

  • Nemocnice Cesky Krumlov

    Český Krumlov, 381 01, Czechia

  • Norcal Endocrinology & Internal Medicine

    San Ramon, California, 94583, United States

  • Noritake Clinic

    Ushiku, 300-1207, Japan

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189, United States

  • Novak Clinical Research - Tucson - North La Cholla Boulevard

    Tucson, Arizona, 85741, United States

  • Olive Takamatsu Medical Clinic

    Takamatsu, 760-0076, Japan

  • Peking University Third Hospital

    Beijing, 100091, China

  • Puerto Rico Health and Wellness Institute

    Dorado, 00646, Puerto Rico

  • RED-Institut GmbH

    Oldenburg, 23758, Germany

  • Shimokitazawa Tomo Clinic

    Tokyo, 155-0031, Japan

  • Sichuan Provincial People's Hospital

    Chengdu, 610072, China

  • Solaris Clinical Research

    Meridian, Idaho, 83646, United States

  • Southern California Clinical Research

    Santa Ana, California, 92701, United States

  • Texas Valley Clinical Research (TVCR) - Mission

    Mission, Texas, 78572, United States

  • The Corvallis Clinic, P.C.

    Corvallis, Oregon, 97330, United States

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang Shi, 471003, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, 150001, China

  • The Institute of Medical Science, Asahi Life Foundation

    Chūōku, 103-0002, Japan

  • The Machuca Foundation

    Las Vegas, Nevada, 89101, United States

  • The Second Affiliated Hospital Chongqing Medical University

    Chongqing, 400010, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, 210011, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, 300211, China

  • The Second People's Hospital of Hefei

    Hefei, 230011, China

  • Tokuyama Clinic

    Mihama-ku,Chiba City, 261-0004, Japan

  • Tokyo-Eki Center-building Clinic

    Chūōku, 103-0027, Japan

  • Tsuchiura Medical & Health Care Center

    Tsuchiura, 300-0012, Japan

  • University of North Carolina Medical Center

    Chapel Hill, North Carolina, 27514, United States

  • Velocity Clinical Research, Dallas

    Dallas, Texas, 75230, United States

  • West Orange Endocrinology P.A.

    Ocoee, Florida, 34761, United States

  • Xuanwu Hospital Capital Medical University

    Beijing, 100053, China

  • Yokohama Minoru Clinic

    Yokohama, 232-0064, Japan

  • Zhongda Hospital Southeast University

    Nanjing, 210009, China

  • Zhujiang Hospital

    Guangzhou, 510280, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.